Skip to main
AMGN

Amgen (AMGN) Stock Forecast & Price Target

Amgen (AMGN) Analyst Ratings

Based on 13 analyst ratings
Hold
Strong Buy 8%
Buy 23%
Hold 62%
Sell 8%
Strong Sell 0%

Bulls say

Amgen's 3Q25 financial performance demonstrated significant growth, with overall sales increasing by 40% compared to 3Q24 and 16 products achieving double-digit growth, highlighted by Repatha's 40% rise in worldwide sales. The company's revenue guidance for FY25 was recently adjusted upward to a range of $35.8 billion to $36.6 billion, indicating strong momentum across its established product franchises, particularly in oncology and rare diseases following strategic acquisitions. Additionally, the increased investment in R&D, projected to grow over 20% in 2025, further positions Amgen for future innovation and sustained financial strength in the biotechnology sector.

Bears say

Amgen's revenue growth is projected to be approximately 1% in 2026 compared to 2025, significantly impacted by anticipated sales declines of around 28% for Prolia and 39% for Xgeva. While the company possesses emerging products in its pipeline, such as MariTide and olpasiran, there is limited visibility on their potential to counterbalance the erosion of revenue from established products due to impending loss of exclusivity. Additionally, management's indication of muted R&D growth relative to prior years raises concerns about the company's ability to develop new long-term growth drivers in the face of these structural challenges.

Amgen (AMGN) has been analyzed by 13 analysts, with a consensus rating of Hold. 8% of analysts recommend a Strong Buy, 23% recommend Buy, 62% suggest Holding, 8% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Amgen and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Amgen (AMGN) Forecast

Analysts have given Amgen (AMGN) a Hold based on their latest research and market trends.

According to 13 analysts, Amgen (AMGN) has a Hold consensus rating as of Feb 4, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $323.92, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $323.92, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Amgen (AMGN)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.